Details of the Investigation

Investors who believe they may be affected are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com or by calling 646-581-9980, ext. 7980. The essence of the investigation revolves around a significant announcement made by Anavex on November 14, 2025.

On that date, Anavex disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a negative trend vote on the company’s Marketing Authorisation Application (MAA) for the drug blarcamesine.

Market Impact

This announcement had an immediate and severe impact on Anavex’s stock price, which plummeted by $2.05 per share, representing a dramatic 35.94% decline, closing at $3.65 per share the same day. The fallout from this news raises significant questions about the company's compliance with securities laws and its obligations to investors.

Pomerantz LLP: A Leader in Securities Class Action Litigation

Pomerantz LLP is recognized as one of the foremost legal firms specializing in corporate, securities, and antitrust class action litigation, with offices in multiple major cities around the world, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. Founded by the late Abraham L. Pomerantz, the firm has a rich history of advocating for victims of securities fraud and corporate misconduct.

With over 85 years of experience, Pomerantz continues to fight diligently for the rights of investors. The firm has successfully secured numerous multimillion-dollar awards on behalf of its class members, further establishing its reputation in the field of class actions.

Contact Information

Investors wishing to learn more about their rights and the potential implications of the ongoing investigation can contact:

• Name: Danielle Peyton
• Firm: Pomerantz LLP
• Email: dpeyton@pomlaw.com
• Phone: 646-581-9980 ext. 7980